The Effects of Chemotherapeutic Stress on NAT10 Expression in U937 Cells
Session Number
Project ID: BIO 03
Advisor(s)
Dr. Sweta Raikundalia, Dr. Daniel Arango, Northwestern University, Feinberg School of Medicine
Discipline
Biology
Start Date
17-4-2024 8:15 AM
End Date
17-4-2024 8:30 AM
Abstract
The efficacy of chemotherapeutic drug regimens has been a longstanding concern for cancer treatments, highlighting the need for research on how they could become more effective. A possible answer could lie in the field of epitranscriptomics, in which chemical modifications are made to RNA to affect gene expression. In this study, we aimed to find the effects of drug treatment duration on the expression levels and subcellular location of N- acetyltransferase 10 (NAT10), an enzyme that has been associated with poor prognosis in multiple cancer types. Weobserved an increase in NAT10 levels as the duration of Daunorubicin treatment increased, yet our results with Cytarabine were inconclusive, leaving room for further experimentation. Additionally, we found that there was increased NAT10 expression in the cytoplasm when treated with Daunorubicin, but decreased expression when treated with Cytarabine. While our results put NAT10 as a promising drug target for AML patients, further research is needed to validate these findings. Doing so will help us uncover the implications of NAT10 expression and localization in drug resistance and cancer progression.
The Effects of Chemotherapeutic Stress on NAT10 Expression in U937 Cells
The efficacy of chemotherapeutic drug regimens has been a longstanding concern for cancer treatments, highlighting the need for research on how they could become more effective. A possible answer could lie in the field of epitranscriptomics, in which chemical modifications are made to RNA to affect gene expression. In this study, we aimed to find the effects of drug treatment duration on the expression levels and subcellular location of N- acetyltransferase 10 (NAT10), an enzyme that has been associated with poor prognosis in multiple cancer types. Weobserved an increase in NAT10 levels as the duration of Daunorubicin treatment increased, yet our results with Cytarabine were inconclusive, leaving room for further experimentation. Additionally, we found that there was increased NAT10 expression in the cytoplasm when treated with Daunorubicin, but decreased expression when treated with Cytarabine. While our results put NAT10 as a promising drug target for AML patients, further research is needed to validate these findings. Doing so will help us uncover the implications of NAT10 expression and localization in drug resistance and cancer progression.